Association study and meta-analysis of polymorphisms, methylation profiles, and peripheral mRNA expression of the serotonin transporter gene in patients with Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 41, Issue 5-6, 2016, Pages 334-347

  Yamazaki, Kiyohiro ^a   Yoshino, Yuta ^a   Mori, Takaaki ^a   Okita, Mitsuo ^a   Yoshida, Taku ^a   Mori, Yoko ^a   Ozaki, Yuki ^a   Sao, Tomoko ^a   Iga, Jun Ichi ^a   Ueno, Shu Ichi ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alzheimers disease; Apathy; Epigenetics; Meta analysis; mRNA; Serotonin transporter

Indexed keywords

MESSENGER RNA; SEROTONIN TRANSPORTER; SLC6A4 PROTEIN, HUMAN; TRANSCRIPTOME;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HUMAN; HUMAN CELL; LEUKOCYTE; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; RISK REDUCTION; SEROTONIN TRANSPORTER GENE; GENETICS; META ANALYSIS;

ALZHEIMER DISEASE; HUMANS; METHYLATION; POLYMORPHISM, GENETIC; RNA, MESSENGER; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TRANSCRIPTOME;

EID: 84979036021     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000447324     Document Type: Article

References (76)

1. Jorm AF: Effects of cholinergic enhancement therapies on memory function in Alzheimers disease: a metaanalysis of the literature. Aust NZ J Psychiatry 1986; 20: 237-240.
2. Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J: Cholinesterase inhibitors used in the treatment of Alzheimers disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging 2004; 21: 453-478.
3. Frazer A, Hensler JG: Molecular, cellular and medical aspects; in Siegel JS, Agranoff BW, Albers RW, Molinoff PB (eds): Basic Neurochemistry, ed 5. Philadelphia, Lippincott-Raven, 1994, pp 283-308.
4. Hornung JP: The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003; 26: 331-343.
5. Fujita M, Shimada S, Maeno H, Nishimura T, Tohyama M: Cellular localization of serotonin transporter mRNA in the rat brain. Neurosci Lett 1993; 162: 59-62.
6. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP: Allelic variation of human serotonin transporter gene expression. J Neurochem 1996; 66: 2621-2624.
7. Karg K, Burmeister M, Shedden K, Sen S: The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011; 68: 444-454.
8. Nakamura M, Ueno S, Sano A, Tanabe H: The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000; 5: 32-38.
9. Kraft JB, Slager SL, McGrath PJ, Hamilton SP: Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374-381.
10. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D: Serotonin transporter promoter gain-of-function genotypes are linked to obsessivecompulsive disorder. Am J Hum Genet 2006; 78: 815-826.
11. Ehli EA, Hu Y, Lengyel-Nelson T, Hudziak JJ, Davies GE: Identification and functional characterization of three novel alleles for the serotonin transporter-linked polymorphic region. Mol Psychiatry 2012; 17: 185-192.
12. Seripa D, Iurescia S, Rinaldi M, Pilotto A, Paroni G, Bazzano S, Antonelli A, Gravina C, Urbano M, Padovani A, Pilotto A: The serotonin transporter gene-linked polymorphic region: identification and functional characterization of novel alleles. Eur Geriatr Med 2013; 4:S100.
13. Philibert R, Madan A, Andersen A, Cadoret R, Packer H, Sandhu H: Serotonin transporter mRNA levels are associated with the methylation of an upstream CpG island. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:101-105.
14. Wankerl M, Miller R, Kirschbaum C, Hennig J, Stalder T, Alexander N: Effects of genetic and early environmental risk factors for depression on serotonin transporter expression and methylation profiles. Transl Psychiatry 2014; 4:e402.
15. Sukonick DL, Pollock BG, Sweet RA, Mulsant BH, Rosen J, Klunk WE, Kastango KB, DeKosky ST, Ferrell RE: The 5-HTTPR S/L polymorphism and aggressive behaviour in Alzheimers disease. Arch Neurol 2001; 58: 1425-1428.
16. Sweet RA, Pollock BG, Sukonick DL, Mulsant BH, Rosen J, Klunk WE, Kastango KB, DeKosky ST, Ferrell RE: The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr 2001; 13: 401-409.
17. Borroni B, Grassi M, Agosti C, Archetti S, Costanzi C, Cornali C, Caltagirone C, Caimi L, Di Luca M, Padovani A: Cumulative effect of COMT and 5-HTTLPR polymorphisms and their interaction with disease severity and comorbidities on the risk of psychosis in Alzheimer disease. Am J Geriatr Psychiatry 2006; 14: 343-351.
18. Pitchard AL, Pritchard CW, Bentham P, Lendon CL: Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord 2007; 24: 201-206.
19. Quaranta D, Bizzarro A, Marra C, Vita MG, Seripa D, Pilotto A, Sebastiani V, Mecocci P, Masullo C: Psychotic symptoms in Alzheimers disease and 5-HTTLPR polymorphism of the serotonin transporter gene: evidence for an association. J Alzheimers Dis 2009; 16: 173-180.
20. Proitsi P, Lupton MK, Reeves SJ, Hamilton G, Archer N, Martin BM, Iyegbe C, Hollingworth P, Lawlor B, Gill M, Brayne C, Rubinsztein DC, Owen MJ, Williams J, Lovestone S, Powell JF: Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging 2012; 33: 791-803.
21. Li T, Holmes C, Sham PC, Vallada H, Birkett J, Kirov G, Lesch KP, Powell J, Lovestone S, Collier D: Allelic functional variation of serotonin transporter expression is a susceptibility factor for late onset Alzheimers disease. Neuroreport 1997; 8: 683-686.
22. Rocchi A, Micheli D, Ceravolo R, Manca ML, Tognoni G, Siciliano G, Murri L: Serotoninergic polymorphisms (5-HTTLPR and 5-HT2A): association studies with psychosis in Alzheimer disease. Genet Test 2003; 7: 309-314.
23. Assal F, Alarcon M, Solomon EC, Masterman D, Geschwind DH, Cummings JL: Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol 2004; 61: 1249-1253.
24. Ha TM, Cho DM, Park SW, Joo MJ, Lee BJ, Kong BG, Kim JM, Yoon JS, Kim YH: Evaluating associations between 5-HTTLPR polymorphism and Alzheimers disease for Korean patients. Dement Geriatr Cogn Disord 2005; 20: 31-34.
25. Micheli D, Bonvicini C, Rocchi A, Ceravolo R, Mancuso M, Tognoni G, Gennarelli M, Siciliano G, Murri L: No evidence for allelic association of serotonin 2A receptor and transporter gene polymorphisms with depression in Alzheimer disease. J Alzheimers Dis 2006; 10: 371-378.
26. Ueki A, Ueno H, Sato N, Shinjo H, Morita Y: Serotonin transporter gene polymorphism and BPSD in mild Alzheimers disease. J Alzheimers Dis 2007; 12: 245-253.
27. Grunblatt E, Zehetmayer S, Bartl J, Loffler C, Wichart I, Rainer MK, Jungwirth S, Bauer P, Danielczyk W, Tragl KH, Riederer P, Fischer P: Genetic risk factors and markers for Alzheimers disease and/or depression in the VITA study. J Psychiatr Res 2009; 43: 298-308.
28. Albani D, Prato F, Tettamanti M, Lovati C, Galimberti D, Restelli I, Mariani C, Quadri PL, Scarpini E, Lucca U, Forloni G.: The serotonin transporter promoter polymorphic region is not a risk factor for Alzheimers disease related behavioral disturbances. J Alzheimers Dis 2009; 18: 125-130.
29. Iga J, Ueno S, Yamauchi K, Motoki I, Tayoshi S, Ohta K, Song H, Morita K, Rokutan K, Ohmori T: Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine. Neurosci Lett 2005; 389: 12-16.
30. Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR: Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 899-905.
31. Thomas AJ, Hendriksen M, Piggott M, Ferrier IN, Perry E, Ince P, O'Brien JT: A study of the serotonin transporter in the prefrontal cortex in late-life depression and Alzheimers disease with and without depression. Neuropathol Appl Neurobiol 2006; 32: 296-303.
32. Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS: Disturbed neurotransmitter transporter expression in Alzheimers disease brain. J Alzheimers Dis 2011; 26: 755-766.
33. Creese B, Ballard C, Jones E: Cognitive impairment in studies of 5HTTLPR and psychosis in Alzheimers disease: a systematic review. Dement Geriatr Cogn Disord 2013; 35: 155-164.
34. Watanabe SY, Iga J, Numata S, Umehara H, Nishi A, Kinoshita M, Inoshita M, Ohmori T: Polymorphism in the promoter of the gene for the serotonin transporter affects the age of onset of major depressive disorder in the Japanese population. J Affect Disord 2015; 183: 156-158.
35. Ouchi Y, Yoshikawa E, Futatsubashi M, Yagi S, Ueki T, Nakamura K: Altered brain serotonin transporter and associated glucose metabolism in Alzheimer disease. J Nucl Med 2009; 50: 1260-1266.
36. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement 2011; 7: 263-269.
37. Folstein MF, Folstein SE, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
38. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
39. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-2314.
40. De Luca V, Tharmalingam S, King N, Strauss J, Bulgin N, Kennedy JL: Association study of a novel functional polymorphism of the serotonin transporter gene in bipolar disorder and suicidal behavior. Psychopharmacology (Berl) 2005; 182: 128-131.
41. De Luca V, Zai G, Tharmalingam S, de Bartolomeis A, Wong G, Kennedy JL: Association study between the novel functional polymorphism of the serotonin transporter gene and suicidal behavior in schizophrenia. Eur Neuropsychopharmacol 2006; 6: 268-271.
42. Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, Ginovart N, Tharmalingam S, Masellis M, Houle S, Meyer JH: Novel 5-HTTLPR allele associates with higher serotonin transporter binding in putamen: a [(11)C] DASB positron emission tomography study. Biol Psychiatry 2007; 62: 327-331.
43. Mortensen OV, Thomassen M, Larsen MB, Whittemore SR, Wiborg O: Functional analysis of a novel human serotonin transporter gene promoter in immortalized raphe cells. Brain Res Mol Brain Res 1999; 68: 141-148.
44. Carrol ED, Salway F, Pepper SD, Saunders E, Mankhambo LA, Ollier WE, Hart CA, Day P: Successful downstream application of the Paxgene Blood RNA system from small blood samples in paediatric patients for quantitative PCR analysis. BMC Immunol 2007; 8: 20.
45. Hu N, Tan MS, Yu JT, Sun L, Tan L, Wang YL, Jiang T, Tan L: Increased expression of TREM2 in peripheral blood of Alzheimers disease patients. J Alzheimers Dis 2014; 38: 497-501.
46. Watanabe S, Iga J, Nishi A, Numata S, Kinoshita M, Kikuchi K, Nakataki M, Ohmori T: Microarray analysis of global gene expression in leukocytes following lithium treatment. Hum Psychopharmacol Clin Exp 2014; 29: 190-198.
47. Watanabe SY, Iga J, Ishii K, Numata S, Shimodera S, Fujita H, Ohmori T: Biological tests for major depressive disorder that involve leukocyte gene expression assays. J Psychiatr Res 2015; 66-67: 1-6.
48. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
49. Kanda Y: Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transplant 2013; 48: 452-458.
50. Bradley SL, Dodelzon K, Sandhu HK, Philibert RA: Relationship of serotonin transporter gene polymorphisms and haplotypes to mRNA transcription. Am J Med Genet B Neuropsychiatr Genet 2005; 136B:58-61.
51. Talati A, Guffanti G, Odgerel Z, Ionita-Laza I, Malm H, Sourander A, Brown AS, Wickramaratne PJ, Gingrich JA, Weissman MM: Genetic variants within the serotonin transporter associated with familial risk for major depression. Psychiatry Res 2015; 228: 170-173.
52. Kunugi H, Ueki A, Otsuka M, Isse K, Hirasawa H, Kato N, Nabika T, Kobayashi S, Nanko S: Alzheimers disease and 5-HTTLPR polymorphism of the serotonin transporter gene: no evidence for an association. Am J Med Genet 2000; 96: 307-309.
53. Tsai SJ, Hong CJ, Liu TY, Cheng CY, Liu HC: Association study for a functional serotonin transporter gene polymorphism and late-onset Alzheimers disease for Chinese patients. Neuropsychobiology 2001; 44: 27-30.
54. Feher A, Juhasz A, Laszlo A, Pakaski M, Kalman J, Janka Z: Serotonin transporter and serotonin receptor 2A gene polymorphisms in Alzheimers disease. Neurosci Lett 2013; 534: 233-236.
55. Lorenzi C, Marcone A, Pirovano A, Marino E, Cordici F, Cerami C, Delmonte D, Cappa SF, Bramanti P, Smeraldi E: Serotonin transporter and saitohin genes in risk of Alzheimers disease and frontotemporal lobar dementia: preliminary findings. Neurol Sci 2010; 31: 741-749.
56. Seripa D, Franceschi M, D'Onofrio G, Panza F, Cascavilla L, Paris F, Placentino G, Matera MG, Solfrizzi V, Pilotto A: Polymorphism C in the serotonin transporter gene (SLC6A4) in questionable dementia and Alzheimers disease. Neurosci Lett 2008; 438: 335-339.
57. Nishimura AL, Guindalini C, Oliveira JR, Nitrini R, Bahia VS, de Brito-Marques PR, Otto PA, Zatz M: Monoamine oxidase a polymorphism in Brazilian patients: risk factor for late-onset Alzheimers disease? J Mol Neurosci 2005; 27: 213-217.
58. Zill P, Padberg F, de Jonge S, Hampel H, Burger K, Stubner S, Boetsch T, Jurgen Moller H, Ackenheil M, Bondy B: Serotonin transporter (5-HTT) gene polymorphism in psychogeriatric patients. Neurosci Lett 2000; 284: 113-115.
59. Oliveira JR, Gallindo RM, Maia LG, Brito-Marques PR, Otto PA, Passos-Bueno MR, Morais MA Jr, Zatz M: The short variant of the polymorphism within the promoter region of the serotonin transporter gene is a risk factor for late onset Alzheimers disease. Mol Psychiatry 1998; 3: 438-441.
60. Porcelli S, Fabbri C, Serretti A: Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012; 22: 239-258.
61. Watanabe SY, Iga J, Ishii K, Numata S, Shimodera S, Fujita H, Ohmori T: Biological tests for major depressive disorder that involve leukocyte gene expression assays. J Psychiatr Res 2015; 66-67: 1-6.
62. Martin J, Cleak J, Willis-Owen SAG, Flint J, Shifman S: Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance. Mol Psychiatry 2007; 12: 421-422.
63. Murthy NV, Selvaraj S, Cowen PJ, Bhagwagar Z, Riedel WJ, Peers P, Kennedy JL, Sahakian BJ, Laruelle MA, Rabiner EA, Grasby PM: Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. Neuroimage 2010; 52: 50-54.
64. Gao Z, Yuan H, Sun M, Wang Z, He Y, Liu D: The association of serotonin transporter gene polymorphism and geriatric depression: a meta-analysis. Neurosci Lett 2014; 578: 148-152.
65. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH: Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004; 9: 433-441.
66. Goldman N, Glei DA, Lin, YH, Weinstein M: The serotonin transporter polymorphism (5-HTTLPR): allelic variation and links with depressive symptoms. Depress Anxiety 2010; 27: 260-269.
67. Murphy DL, Moya PR: Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional GxG and GxE differences in health and disease. Curr Opin Pharmacol 2011; 11: 3-10.
68. Kim JM, Stewart R, Kang HJ, Kim SW, Shin IS, Kim HR, Shin MG, Kim JT, Park MS, Cho KH, Yoon JS: A longitudinal study of SLC6A4 DNA promoter methylation and poststroke depression. J Psychiatr Res 2013; 47: 1222-1227.
69. Domschke K, Tidow N, Schwarte K, Deckert J, Lesch KP, Arolt V, Zwanzger P, Baune BT: Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol 2014; 17: 1167-1176.
70. Devlin AM, Brain U, Austin J, Oberlander TF: Prenatal exposure to maternal depressed mood and the MTHFR C677T variant affect SLC6A4 methylation in infants at birth. PLoS One 2010; 5:e12201.
71. Alasaari JS, Lagus M, Ollila HM, Toivola A, Kivimaki M, Vahtera J, Kronholm E, Harma M, Puttonen S, Paunio T: Environmental stress affects DNA methylation of a CpG rich promoter region of serotonin transporter gene in a nurse cohort. PLoS One 2012; 7:e45813.
72. Kang HJ, Kim JM, Stewart R, Kim SY, Bae KY, Kim SW, Shin IS, Shin MG, Yoon JS: Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. Prog Neuropsychopharmacol Biol Psychiatry 2013; 44: 23-28.
73. Okada S, Morinobu S, Fuchikami M, Segawa M, Yokomaku K, Kataoka T, Okamoto Y, Yamawaki S, Inoue T, Kusumi I, Koyama T, Tsuchiyama K, Terao T, Kokubo Y, Mimura M: The potential of SLC6A4 gene methylation analysis for the diagnosis and treatment of major depression. J Psychiatr Res 2014; 53: 47-53.
74. Philibert RA, Sandhu H, Hollenbeck N, Gunter T, Adams W, Madan A: The relationship of 5HTT (SLC6A4) methylation and genotype on mRNA expression and liability to major depression and alcohol dependence in subjects from the Iowa Adoption Studies. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:543-549.
75. Belzeaux R, Azorin JM, Ibrahim EC: Monitoring candidate gene expression variations before, during and after a first major depressive episode in a 51-year-old man. BMC Psychiatry 2014; 14: 73.
76. Mori T, Shimada H, Shinotoh H, Hirano S, Eguchi Y, Yamada M, Fukuhara R, Tanimukai S, Zhang MR, Kuwabara S, Ueno S, Suhara T: Apathy correlates with prefrontal amyloid β deposition in Alzheimers disease. J Neurol Neurosurg Psychiatry 2013; 85: 449-455.